Longevity compound
NMN
Automated longevity evidence pipeline intervention.
Where the science stands
This page summarizes the current human evidence captured in the Longevity Compass database. Result interpretation is conservative and unresolved outcomes remain unknown.
Research path
From biological idea to human evidence
These stages show different kinds of evidence for NMN. Moving through them does not mean an intervention is proven to slow aging.
- 1
Biological idea
Reviewing animal and laboratory research…
- 2
Human testing
8 direct aging trial links and 4 related trial links tracked. A trial count describes research activity, not benefit.
- 3
What results show
0 beneficial, 0 neutral and 0 harmful result links interpreted; 0 remain unresolved.
- 4
Still unanswered
Whether these findings translate into meaningful, lasting healthy-aging benefits in people remains unproven. Longer follow-up and clearer safety and clinical outcomes are needed.
Beyond human trials
The bigger longevity story
Loading animal and laboratory evidence…
Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.
Research depth
Human evidence picture
Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.
8
Direct aging trials
4
Indirect relevant trials
11
Publications linked
2
Results publications
Interpreted results
- Beneficial
- 0
- Neutral
- 0
- Harmful
- 0
- Unknown / unresolved
- 0
Population relevance
- Healthy / aging
- 5
- Disease-specific
- 1
Safety evidence
0
Trials currently identified with safety-result data.
Go to the source
Studies & publications
Inspect the original evidence behind this profile. Links open the trial registry, PubMed or the publication DOI.
Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult ParticipantsNCT06889740INTERVENTIONAL · NA · 80 participants · COMPLETEDPRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)NCT07451496INTERVENTIONAL · NA · 20 participants · RECRUITINGNicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older AdultsNCT07144527INTERVENTIONAL · NA · 40 participants · RECRUITINGIntervention of Nicotinamide Mononucleotide in Middle-aged and Elderly PeopleNCT06592859INTERVENTIONAL · NA · 240 participants · RECRUITINGNAD Augmentation in Diabetes Kidney DiseaseNCT05759468INTERVENTIONAL · PHASE2 · 156 participants · RECRUITINGTracing the Metabolic Flux of Orally Administered NAD+ PrecursorsNCT06882096INTERVENTIONAL · PHASE1 · 32 participants · RECRUITINGEvaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3)NCT04228640INTERVENTIONAL · NA · 66 participants · COMPLETEDThe Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.NCT06907329INTERVENTIONAL · NA · 126 participants · RECRUITINGAnti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus PlaceboNCT04685096OBSERVATIONAL · 89 participants · COMPLETEDNicotinamide Mononucleotide in Hypertensive PatientsNCT04903210INTERVENTIONAL · PHASE4 · 20 participants · UNKNOWNThe Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.NCT05984550INTERVENTIONAL · EARLY_PHASE1 · 10 participants · UNKNOWNTo Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) AdultsNCT04823260INTERVENTIONAL · NA · 90 participants · COMPLETEDChandra MS, Gagliano-Juca T, Shekhar S, Pencina KM, Travison TG, Garg R, McDonnell ME, Reid KF, Latham NK, Lam H, Meritus D, Yan Y, Isaza I, Weiss MF, Beleva YM, Bracken EM, Ruiz E, Wang C, Forman J, Waikar SS, Bhasin S. Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol. Kidney Int Rep. 2026 Jul 16;11(10):106700. doi: 10.1016/j.ekir.2026.106700. eCollection 2026 Oct.PMID 42603990Results publicationYi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023 Feb;45(1):29-43. doi: 10.1007/s11357-022-00705-1. Epub 2022 Dec 8.PMID 36482258Results publicationSauve AA, Wang Q, Zhang N, Kang S, Rathmann A, Yang Y. Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD+ Biosynthesis in Whole Mice. Int J Mol Sci. 2023 Jul 5;24(13):11114. doi: 10.3390/ijms241311114.PMID 37446292Linked publicationAmjad S, Nisar S, Bhat AA, Shah AR, Frenneaux MP, Fakhro K, Haris M, Reddy R, Patay Z, Baur J, Bagga P. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol Metab. 2021 Jul;49:101195. doi: 10.1016/j.molmet.2021.101195. Epub 2021 Feb 17.PMID 33609766Linked publicationPencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):90-96. doi: 10.1093/gerona/glac049.PMID 35182418Linked publicationPencina KM, Valderrabano R, Wipper B, Orkaby AR, Reid KF, Storer T, Lin AP, Merugumala S, Wilson L, Latham N, Ghattas-Puylara C, Ozimek NE, Cheng M, Bhargava A, Memish-Beleva Y, Lawney B, Lavu S, Swain PM, Apte RS, Sinclair DA, Livingston D, Bhasin S. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1968-1980. doi: 10.1210/clinem/dgad027.PMID 36740954Linked publicationDutta T, Kapoor N, Mathew M, Chakraborty SS, Ward NP, Prieto-Farigua N, Falzone A, DeLany JP, Smith SR, Coen PM, DeNicola GM, Gardell SJ. Source of nicotinamide governs its metabolic fate in cultured cells, mice, and humans. Cell Rep. 2023 Mar 28;42(3):112218. doi: 10.1016/j.celrep.2023.112218. Epub 2023 Mar 9.PMID 36897780Linked publicationKim LJ, Chalmers TJ, Madawala R, Smith GC, Li C, Das A, Poon EWK, Wang J, Tucker SP, Sinclair DA, Quek LE, Wu LE. Host-microbiome interactions in nicotinamide mononucleotide (NMN) deamidation. FEBS Lett. 2023 Sep;597(17):2196-2220. doi: 10.1002/1873-3468.14698. Epub 2023 Aug 9.PMID 37463842Linked publicationXiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. Antioxid Redox Signal. 2018 Jan 20;28(3):251-272. doi: 10.1089/ars.2017.7216. Epub 2017 Jul 28.PMID 28648096Linked publicationChellappa K, McReynolds MR, Lu W, Zeng X, Makarov M, Hayat F, Mukherjee S, Bhat YR, Lingala SR, Shima RT, Descamps HC, Cox T, Ji L, Jankowski C, Chu Q, Davidson SM, Thaiss CA, Migaud ME, Rabinowitz JD, Baur JA. NAD precursors cycle between host tissues and the gut microbiome. Cell Metab. 2022 Dec 6;34(12):1947-1959.e5. doi: 10.1016/j.cmet.2022.11.004.PMID 36476934Linked publicationBhasin S, Seals D, Migaud M, Musi N, Baur JA. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocr Rev. 2023 Nov 9;44(6):1047-1073. doi: 10.1210/endrev/bnad019.PMID 37364580Linked publication
The big unanswered question
Can promising biology translate into meaningful healthy-aging benefits?
That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.
Confidence: lowScore model: v0.5-curated-ruleUpdated: 2026-09-21Source: live evidence database